{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:34:47Z","timestamp":1766050487674,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s13760-023-02421-9","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:02:01Z","timestamp":1699963321000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potential beneficial effect of IFN-\u03b21a and ocrelizumab in people with MS during the COVID-19 pandemic"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-7635","authenticated-orcid":false,"given":"Stefan","family":"Todorovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-0308","authenticated-orcid":false,"given":"Slobodan","family":"Vojinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Savi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-4216","authenticated-orcid":false,"given":"Dejan","family":"Aleksi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-5404","authenticated-orcid":false,"given":"Milo\u0161","family":"Danilovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"4","key":"2421_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","volume":"34","author":"J Howard","year":"2016","unstructured":"Howard J, Trevick S, Younger DS (2016) Epidemiology of multiple sclerosis. NeurolClin 34(4):919\u2013939. https:\/\/doi.org\/10.1016\/j.ncl.2016.06.016","journal-title":"NeurolClin"},{"key":"2421_CR2","unstructured":"MSIF (2020) Atlas of MS 2020: Mapping multiple sclerosis around the world. Key Epidemiology Findings. Multiple Sclerosis International Federation"},{"key":"2421_CR3","unstructured":"Tafti D, Ehsan M, Xixis KL (2022) Multiple sclerosis. In: StatPearls [Internet]. Treasure Island (FL). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499849\/"},{"key":"2421_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT et al (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72:152\u2013158","journal-title":"JAMA Neurol"},{"key":"2421_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109884","volume":"143","author":"JJL Jacobs","year":"2020","unstructured":"Jacobs JJL (2020) Neutralizing antibodies mediate virus-immune pathology of COVID-19. Med Hypotheses 143:109884","journal-title":"Med Hypotheses"},{"key":"2421_CR6","doi-asserted-by":"publisher","unstructured":"Filipi M, Jack S (2019) Interferons in the treatment of multiple sclerosis: a clinical efficacy, safety, and tolerability update. Int J MS Care 22(4):165\u2013172. https:\/\/doi.org\/10.7224\/1537-2073.2018-063","DOI":"10.7224\/1537-2073.2018-063"},{"key":"2421_CR7","doi-asserted-by":"publisher","unstructured":"Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS (2017) Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum\/Golgi membrane. J Virol 81(18):9812\u20139824. https:\/\/doi.org\/10.1128\/JVI.01012-07","DOI":"10.1128\/JVI.01012-07"},{"key":"2421_CR8","doi-asserted-by":"publisher","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L (2017) OPERA I and OPERA II clinical investigators. ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","DOI":"10.1056\/NEJMoa1601277"},{"key":"2421_CR9","doi-asserted-by":"publisher","unstructured":"Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, Craveiro L, Dillon P, Bonati U, Jessop N, Pedotti R, Koendgen H (2021) COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord 49:102725. https:\/\/doi.org\/10.1016\/j.msard.2020.102725","DOI":"10.1016\/j.msard.2020.102725"},{"issue":"19","key":"2421_CR10","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","volume":"97","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, De Brouwer E, Kalincik T et al (2021) Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 97(19):e1870\u2013e1885. https:\/\/doi.org\/10.1212\/WNL.0000000000012753","journal-title":"Neurology"},{"issue":"1","key":"2421_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397.PMID:32191675;PMCID:PMC7569573","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91(1):157\u2013160. https:\/\/doi.org\/10.23750\/abm.v91i1.9397.PMID:32191675;PMCID:PMC7569573","journal-title":"Acta Biomed"},{"issue":"10223","key":"2421_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF Chan","year":"2020","unstructured":"Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514\u2013523","journal-title":"Lancet"},{"issue":"10229","key":"2421_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(20)30633-4","volume":"395","author":"P Weiss","year":"2020","unstructured":"Weiss P, Murdoch DR (2020) Clinical course and mortality risk of severe COVID-19. Lancet 395(10229):1014\u20131015","journal-title":"Lancet"},{"key":"2421_CR14","doi-asserted-by":"publisher","first-page":"6372","DOI":"10.7150\/thno.46833","volume":"10","author":"PP Xu","year":"2020","unstructured":"Xu PP, Tian RH, Luo S et al (2020) Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics 10:6372\u20136383","journal-title":"Theranostics"},{"key":"2421_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13561-022-00358-y","volume":"12","author":"D Lupu","year":"2022","unstructured":"Lupu D, Tiganasu R (2022) COVID-19 and the efficiency of health systems in Europe. Health Econ Rev 12:14. https:\/\/doi.org\/10.1186\/s13561-022-00358-y","journal-title":"Health Econ Rev"},{"issue":"11","key":"2421_CR16","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1177\/1352458516681198","volume":"23","author":"JM Wijnands","year":"2017","unstructured":"Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, Marrie RA (2017) Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler 23(11):1506\u20131516. https:\/\/doi.org\/10.1177\/1352458516681198","journal-title":"Mult Scler"},{"key":"2421_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2015.00520","volume":"6","author":"AJ Steelman","year":"2015","unstructured":"Steelman AJ (2015) Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol 6:520. https:\/\/doi.org\/10.3389\/fimmu.2015.00520","journal-title":"Front Immunol"},{"key":"2421_CR18","doi-asserted-by":"publisher","unstructured":"Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M (2022) Italian MS Register. Risk of getting COVID-19 in people with multiple sclerosis: a case\u2013control study. Neurol Neuroimmunol Neuroinflamm 9(2):e1141. https:\/\/doi.org\/10.1212\/NXI.0000000000001141","DOI":"10.1212\/NXI.0000000000001141"},{"key":"2421_CR19","volume":"49","author":"G Mallucci","year":"2021","unstructured":"Mallucci G, Zito A, Baldanti F et al (2021) Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. MultSclerRelatDisord 49:102754","journal-title":"MultSclerRelatDisord"},{"key":"2421_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.12688\/wellcomeopenres.16349.1","volume":"5","author":"PM Fernandes","year":"2020","unstructured":"Fernandes PM, O\u2019Neill M, Kearns PKA et al (2020) Impact of the first COVID-19 pandemic wave on the Scottish Multiple Sclerosis Register population. Wellcome Open Res 5:276","journal-title":"Wellcome Open Res"},{"key":"2421_CR21","doi-asserted-by":"publisher","unstructured":"Costabile T, Carotenuto A, Lavorgna L, Borriello G, Moiola L, Inglese M, Petruzzo M, Trojsi F, Ianniello A, Nozzolillo A, Cellerino M, Boffa G, Rosa L, Servillo G, Moccia M, Bonavita S, Filippi M, Lanzillo R, Brescia Morra V, Petracca M (2020) COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. Eur J Neurol. 28(10):3375\u20133383. https:\/\/doi.org\/10.1111\/ene.14580","DOI":"10.1111\/ene.14580"},{"key":"2421_CR22","unstructured":"Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19, Version 16. Australian National COVID-19 Clinical Evidence Taskforce; 2020 [cited 2020 August 2]. Available from https:\/\/covid19evidence.net.au\/"},{"key":"2421_CR23","unstructured":"Federation MSI (2022) MS, the coronavirus and vaccines\u2014updated global advice. 2021 [cited 2022 Feb 8 2022]. Available from https:\/\/www.msif.org\/news\/2020\/02\/10\/the-coronavirus-and-ms-what-you-nee"},{"key":"2421_CR24","doi-asserted-by":"publisher","unstructured":"Moss BP, Mahajan KR, Bermel RA, Hellisz K, Hua LH, Hudec T, Husak S, McGinley MP, Ontaneda D, Wang Z, Weber M, Tagliani P, C\u00e1rdenas-Robledo S, Zabalza A, Arrambide G, Carbonell-Mirabent P, Rodr\u00edguez-Barranco M, Sastre-Garriga J, Tintore M, Montalban X, Douglas M, Ogbuokiri E, Aravidis B, Cohen JA, Mowry EM, Fitzgerald KC. (2020) Multiple sclerosis management during the COVID-19 pandemic. Mult Scler. 26(10):1163\u20131171. https:\/\/doi.org\/10.1177\/1352458520948231","DOI":"10.1177\/1352458520948231"},{"issue":"4","key":"2421_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000761","volume":"7","author":"JR Berger","year":"2020","unstructured":"Berger JR, Brandstadter R, Bar-Or A (2020) (2020) COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm 7(4):e761. https:\/\/doi.org\/10.1212\/NXI.0000000000000761","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2421_CR26","doi-asserted-by":"publisher","unstructured":"Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA (2021) Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 9(2):196\u2013206. https:\/\/doi.org\/10.1016\/S2213-2600(20)30511-7","DOI":"10.1016\/S2213-2600(20)30511-7"},{"key":"2421_CR27","doi-asserted-by":"publisher","unstructured":"Freedman MS, Jack D, Murgasova Z, Todorovic M, Seitzinger A (2021) Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis. MultSclerRelatDisord 56:103283. https:\/\/doi.org\/10.1016\/j.msard.2021.103283","DOI":"10.1016\/j.msard.2021.103283"},{"issue":"6","key":"2421_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","volume":"78","author":"A Salter","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, Costello K, Bebo B, Rammohan K, Cutter GR, Cross AH (2021) Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol 78(6):699\u2013708. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0688","journal-title":"JAMA Neurol"},{"issue":"2","key":"2421_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3947\/ic.2021.0028","volume":"53","author":"JP Sosa","year":"2021","unstructured":"Sosa JP, Ferreira Caceres MM, Ross Comptis J, Quiros J, Pr\u00edncipe-Meneses FS, Riva-Moscoso A, Belizaire MP, Malanyaon FQ, Agadi K, Jaffery SS, Sahajwani J, Arshia A, Senatus A, Verdecia G, Akano L, Razzack AA, Salam S, Gadamidi VK, Marian S (2021) Effects of interferon beta in COVID-19 adult patients: systematic review. Infect Chemother 53(2):247\u2013260. https:\/\/doi.org\/10.3947\/ic.2021.0028","journal-title":"Infect Chemother"},{"key":"2421_CR30","doi-asserted-by":"publisher","unstructured":"Maniscalco GT, Manzo V, Ferrara AL, Perrella A, Di Battista M, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Barbato S, Servillo G, Longo K, Di Giovanni M, Scarpati B, Muggianu SM, Longo G, Russo G, Andreone V, De Rosa V (2022) Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. MultSclerRelatDisord 58:103455. https:\/\/doi.org\/10.1016\/j.msard.2021.103455","DOI":"10.1016\/j.msard.2021.103455"},{"issue":"2","key":"2421_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/vaccines10020279","volume":"10","author":"M Golshani","year":"2022","unstructured":"Golshani M, Hrdy J (2022) Multiple sclerosis patients and disease modifying therapies: impact on immune responses against COVID-19 and SARS-CoV-2 vaccination. Vaccines 10(2):279. https:\/\/doi.org\/10.3390\/vaccines10020279","journal-title":"Vaccines"},{"issue":"3","key":"2421_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4117","volume":"4","author":"DO Meltzer","year":"2021","unstructured":"Meltzer DO, Best TJ, Zhang H, Vokes T, Arora VM (2021) Association of vitamin D levels, race\/ethnicity, and clinical characteristics with COVID-19 test results. JAMA Netw Open 4(3):e214117. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.4117","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2421_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000622","volume":"6","author":"X Feng","year":"2019","unstructured":"Feng X, Wang Z, Howlett-Prieto Q, Einhorn N, Causevic S (2019) Vitamin D enhances responses to interferon-\u03b2 in MS. Neurol Neuroimmunol Neuroinflamm 6(6):e622. https:\/\/doi.org\/10.1212\/NXI.0000000000000622","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2421_CR34","doi-asserted-by":"publisher","unstructured":"Wu X, Wang L, Shen L, Tang K (2022) Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine 81:104102. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104102","DOI":"10.1016\/j.ebiom.2022.104102"},{"key":"2421_CR35","doi-asserted-by":"publisher","unstructured":"Alroughani R, Inshasi JS, Al-Hashel J, Alkhaboury J, Alsalti A, Suwaidi RA, Hassino LH, Ahmed SF (2022) Incidence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East. Mult Scler Relat Disord 59:103579. https:\/\/doi.org\/10.1016\/j.msard.2022.103579","DOI":"10.1016\/j.msard.2022.103579"},{"key":"2421_CR36","doi-asserted-by":"publisher","unstructured":"Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89(4):780\u2013789. https:\/\/doi.org\/10.1002\/ana.26028","DOI":"10.1002\/ana.26028"},{"issue":"12","key":"2421_CR37","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/jcm9124067","volume":"9","author":"N M\u00f6hn","year":"2020","unstructured":"M\u00f6hn N, Konen FF, Pul R, Kleinschnitz C, Pr\u00fcss H, Witte T, Stangel M (2020) Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases. J Clin Med 9(12):4067. https:\/\/doi.org\/10.3390\/jcm9124067","journal-title":"J Clin Med"},{"key":"2421_CR38","doi-asserted-by":"publisher","unstructured":"Schiavetti I, Ponzano M, Signori A, Bovis F, Carmisciano L, Sormani MP (2022) Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis. MultSclerRelatDisord 57:103358. https:\/\/doi.org\/10.1016\/j.msard.2021.103358","DOI":"10.1016\/j.msard.2021.103358"},{"key":"2421_CR39","doi-asserted-by":"publisher","unstructured":"Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, Craveiro L, Dillon P, Bonati U, Jessop N, Pedotti R, Koendgen H (2020) COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord 49:102725. https:\/\/doi.org\/10.1016\/j.msard.2020.102725","DOI":"10.1016\/j.msard.2020.102725"},{"key":"2421_CR40","doi-asserted-by":"publisher","unstructured":"Inshasi J, Alroughani R, Al-Asmi A, Alkhaboury J, Alsalti A, Boshra A, Canibano B, Deleu D, Ahmed SF, Shatila A, Thakre M (2021) Expert consensus and narrative review on the management of multiple sclerosis in the Arabian Gulf in the COVID-19 era: focus on disease-modifying therapies and vaccination against COVID-19. NeurolTher. 10(2):539\u2013555. https:\/\/doi.org\/10.1007\/s40120-021-00260-5","DOI":"10.1007\/s40120-021-00260-5"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-023-02421-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T06:45:56Z","timestamp":1711435556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-023-02421-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s13760-023-02421-9","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"type":"print","value":"0300-9009"},{"type":"electronic","value":"2240-2993"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"9 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}